Lysogene Announces Presentations at Upcoming Meetings

Regulatory News:

Lysogene (Paris:LYS) (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced the upcoming abstract selected for an oral presentation at the virtual 23^rd ASGCT Annual Meeting and presentations at the EFGCP and NTSAD family conference.

2020 American Society of Gene & Cell Therapy Annual (ASGCT) virtual Meeting
Lysogene will present preclinical results for its gene therapy candidate LYS-GM101 for GM1-Gangliosidosis.

Abstract: Investigational AAV Gene Therapy LYS-GM101 for GM1-Gangliosidosis
Presenter: Ralph Laufer, Lysogene CSO
Date: Friday May 15, 2020
Time: 11:15 AM - 11:30 AM EST
Room: Ballroom A
Register: https://annualmeeting.asgct.org/am20/registration

European Forum for Good Clinical Practice (EFGCP) Webinar
Lysogene will present a novel methodology to collect longitudinal patient-specific home-based video data in mucopolysaccharidosis type IIIA and GM1-gangliosidosis.

Webinar - Digital Tools for Paediatric Clinical Trials
Presenter: Samantha Parker, Lysogene CPO
Date: Monday May 18, 2020
Time: 5:00pm to 6:30pm CEST
Register: http://efgcp.eu/cgi?lg=en&pag=3846&tab=108&rec=124&frm ...

National Tay Sachs and Associated Diseases (NTSAD) Virtual 2020 Family Conference
Lysogene will highlight the design of the GM1-gangliosidosis gene therapy trial.

Webinar - GM1 Research Session
Presenter: Samantha Parker, Lysogene CPO
Date: Friday May 29, 2020
Time: 2:00pm – 3:30pm EST
Register: https://ntsadannualfamilyconference.com/register/

About Lysogene
Lysogene is a gene therapy company focused on the treatment of orphan diseases of the central nervous system (CNS). The company has built a unique capability to enable a safe and effective delivery of gene therapies to the CNS to treat lysosomal diseases and other genetic disorders of the CNS. A phase 2/3 clinical trial in MPS IIIA in partnership with Sarepta Therapeutics, Inc. is ongoing and a phase 1/3 clinical trial in GM1 gangliosidosis is in preparation. In accordance with the agreements signed between Lysogene and Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc. will hold exclusive commercial rights to LYS-SAF302 in the United States and markets outside Europe; and Lysogene will maintain commercial exclusivity of LYS-SAF302 in Europe. Lysogene is also collaborating with an academic partner to define the strategy of development for the treatment of Fragile X syndrome, a genetic disease related to autism. www.lysogene.com.